1.315

5.19% -0.035

Alzamend Neuro Inc (ALZN)

Overview News Price History Financials Why ALZN Down? Discussions Forecast Stock Split

Alzamend Neuro Inc stock is traded at $1.315, with a volume of 19,758. It is down -5.19% in the last 24 hours and down -6.57% over the past month. Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Previous Close:

$1.35

Open:

$1.31

24h Volume:

19,758

Relative Volume:

0.16

Market Cap:

$5.11M

Revenue:

Net Income/Loss:

$-7.04M

P/E Ratio:

-0.3003

EPS:

-4.3784

Net Cash Flow:

$-6.17M

1W Performance:

+4.92%

1M Performance:

-6.57%

6M Performance:

-41.82%

1Y Performance:

-57.48%

1-Day Range:

$1.23

$1.3425

1-Week Range:

$1.16

$1.37

52-Week Range:

$0.84

$3.04

Alzamend Neuro Inc Stock (ALZN) Company Profile

Name

Alzamend Neuro Inc

Sector

Healthcare (1081)

Industry

Biotechnology (601)

Phone

844-722-6333

Address

480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA

Employee

Twitter

Next Earnings Date

2026-07-28

Latest SEC Filings

ALZN's Discussions on Twitter

Compare ALZN vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALZN Alzamend Neuro Inc	1.3425	5.14M	0	-7.04M	-6.17M	-4.3784
VRTX Vertex Pharmaceuticals Inc	474.27	119.94B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	650.38	68.27B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	908.88	53.28B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.96	38.91B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	268.00	35.65B	4.29B	577.22M	641.34M	4.2086

Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-01-21	Initiated	Ascendiant Capital Markets	Buy

Alzamend Neuro Inc Stock (ALZN) Latest News

Jul 22, 2026

Alzamend Neuro FY 2026: Revenue $0 EPS $(2.63) — 10-K Summary - TradingView

Jul 22, 2026

Jul 21, 2026

Alzamend Neuro Announces Passing of Director Fahey McGrath, Ph.D. in July 2026 – SEC 8-K Filing Details 7 - Minichart

Jul 21, 2026

Alzamend Neuro Announces Passing of Board Director - TipRanks

Jul 21, 2026

Jul 17, 2026

Alzamend Neuro Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView

Jul 17, 2026

Jul 10, 2026

Price to sales forward of Alzamend Neuro, Inc. – BOATS:ALZN - TradingView

Jul 10, 2026

Jul 05, 2026

ALZN Q2 2026 Earnings: Narrower-than-expected loss sparks positive market reactionFiscal Year Earnings - dars.gov.et

Jul 05, 2026

Jul 03, 2026

ALZN Q2 2026 Earnings: EPS Beat by 70% but No Revenue – Stock Jumps on SurpriseGuidance Upgrade Report - dars.gov.et

Jul 03, 2026

Jun 30, 2026

Alzamend Neuro (ALZN) Slips 3.1% as Stock Tests Key Support at $1.19Rounding Bottom - DonanımHaber

Jun 26, 2026

Enterprise value to revenue forward of Alzamend Neuro, Inc. – NASDAQ:ALZN - TradingView

Jun 26, 2026

Price to sales forward of Alzamend Neuro, Inc. – NASDAQ:ALZN - TradingView

Jun 26, 2026

Jun 24, 2026

ALZN Q4'25 Earnings: revenue estimate is 0 USD - TradingView

Jun 24, 2026

ALZN Q1 2026 Earnings: Narrower-Than-Expected Loss SurprisesFiscal Year Earnings - dars.gov.et

Jun 24, 2026

Jun 20, 2026